Acrivon Therapeutics, Inc.
ACRV
$1.33
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.51% | -1.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.56% | -13.19% | |||
| Operating Income | -4.56% | 13.19% | |||
| Income Before Tax | -6.74% | 13.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.74% | 13.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.74% | 13.80% | |||
| EBIT | -4.56% | 13.19% | |||
| EBITDA | -4.51% | 13.39% | |||
| EPS Basic | -6.43% | 14.04% | |||
| Normalized Basic EPS | -6.42% | 17.30% | |||
| EPS Diluted | -6.43% | 14.04% | |||
| Normalized Diluted EPS | -6.42% | 17.30% | |||
| Average Basic Shares Outstanding | 0.29% | 0.28% | |||
| Average Diluted Shares Outstanding | 0.29% | 0.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||